Morris Zachary S, McClatchey Andrea I
Massachusetts General Hospital Center for Cancer Research and Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA.
Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9767-72. doi: 10.1073/pnas.0902031106. Epub 2009 Jun 1.
The epidermal growth factor receptor (EGFR) has frequently been implicated in hyperproliferative diseases of renal tubule epithelia. We have shown that the NF2 tumor suppressor Merlin inhibits EGFR internalization and signaling in a cell contact-dependent manner. Interestingly, despite the paucity of recurring mutations in human renal cell carcinoma (RCC), homozygous mutation of the NF2 gene is found in approximately 2% of RCC patient samples in the Sanger COSMIC database. To examine the roles of Merlin and EGFR in kidney tumorigenesis, we generated mice with a targeted deletion of Nf2 in the proximal convoluted epithelium using a Villin-Cre transgene. All of these mice developed intratubular neoplasia by 3 months, which progressed to invasive carcinoma by 6-10 months. Kidneys from these mice demonstrated marked hyperproliferation and a concomitant increase in label-retaining putative progenitor cells. Early lumen-filling lesions in this model exhibited hyperactivation of EGFR signaling, altered solubility of adherens junctions components, and loss of epithelial polarity. Renal cortical epithelial cells derived from either early or late lesions were dependent on EGF for in vitro proliferation and were arrested by pharmacologic inhibition of EGFR or re-expression of Nf2. These cells formed malignant tumors upon s.c. injection into immunocompromised mice before in vitro passage. Treatment of Vil-Cre;Nf2(lox/lox) mice with the EGFR inhibitor erlotinib halted the proliferation of tumor cells. These studies give added credence to the role of EGFR signaling and perhaps Nf2 deficiency in RCC and describe a rare and valuable mouse model for exploring the molecular basis of this disease.
表皮生长因子受体(EGFR)常与肾小管上皮的过度增殖性疾病有关。我们已经表明,NF2肿瘤抑制因子Merlin以细胞接触依赖的方式抑制EGFR的内化和信号传导。有趣的是,尽管人类肾细胞癌(RCC)中反复出现的突变很少,但在Sanger COSMIC数据库中约2%的RCC患者样本中发现了NF2基因的纯合突变。为了研究Merlin和EGFR在肾肿瘤发生中的作用,我们使用Villin-Cre转基因在近端曲管上皮中靶向缺失Nf2基因,生成了小鼠。所有这些小鼠在3个月时都发生了肾小管内瘤变,并在6至10个月时发展为浸润性癌。这些小鼠的肾脏表现出明显的过度增殖,同时标记保留的假定祖细胞数量增加。该模型中早期的管腔填充性病变表现出EGFR信号的过度激活、黏附连接成分溶解度的改变以及上皮极性的丧失。来自早期或晚期病变的肾皮质上皮细胞在体外增殖依赖于表皮生长因子(EGF),并通过EGFR的药物抑制或Nf2的重新表达而停滞。这些细胞在体外传代前皮下注射到免疫缺陷小鼠体内后形成恶性肿瘤。用EGFR抑制剂厄洛替尼治疗Vil-Cre;Nf2(lox/lox)小鼠可使肿瘤细胞的增殖停止。这些研究进一步证实了EGFR信号传导以及可能的Nf2缺陷在RCC中的作用,并描述了一种罕见且有价值的小鼠模型,用于探索这种疾病的分子基础。